Abstract
The potential relevance of chromosome 7q21–22 in susceptibility to multiple sclerosis (MS) has been highlighted in genome-wide linkage screens as well as in association studies of 7q-specific polymorphic microsatellites. Especially, recent, independently performed studies have provided evidence for significant association of the markers D7S554 and D7S3126 with MS in Sardinian, Northern Irish and Spanish–American cohorts. The gene most closely located to these markers is the neuropeptide preprotachykinin-1 (TAC1) gene. Both its position and the array of biological functions exerted by its expression products make it a logical primary choice for further scrutiny as the putative chromosome 7q21–22 MS susceptibility gene. We report identification of eight polymorphisms in this gene by means of a sequencing approach. A Northern Irish case–control was typed for six of these polymorphisms. One of these, an intron 1 single-nucleotide polymorphism (SNP), showed significant association with MS (P=0.009). Two-marker haplotypes composed of allelic combinations of TAC1 promoter–intron 1 SNPs were highly significantly associated with MS and more so with the relapsing-remitting form of this disease. While independent reproduction of these data in other data sets is indicated, our work is suggestive for a role of the TAC1 gene in MS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout


Similar content being viewed by others
References
Compston A, Coles A . Multiple sclerosis. Lancet 2002; 359: 1221–1231.
Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL . Multiple sclerosis: genomic rewards. J Neuroimmunol 2001; 113: 171–184.
Kantarci OH, de Andrade M, Weinshenker BG . Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144–159.
Vandenbroeck K, Goris A . Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci 2003; 24: 284–289.
Vandenbroeck K, Fiten P, Heggarty S et al. Chromosome 7q21–22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the preprotachykinin-1 gene. J Neuroimmunol 2002; 125: 141–148.
Villoslada P, Oksenberg JR, Barcellos LF . Chromosome 7q21–22 and multiple sclerosis. J Neuroimmunol 2004; 150: 1–2.
Haines JL, Ter-Minassian M, Bazyk A et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996; 13: 469–471.
Haines JL, Badford Y, Garcia M et al. Multiple loci for multiple sclerosis. Hum Mol Genet 2002; 11: 2251–2256.
Ardlie KG, Kruglyak L, Seielstad M . Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3: 299–309.
Kwok PY . SNP genotyping with fluorescence polarization detection. Hum Mutat 2002; 19: 315–323.
Henry M, Chomiki N, Scarabin PY et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17: 851–858.
Jones KA, Porjesz B, Almasy L et al. Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: implications for human brain dynamics and cognition. Int J Psychophysiol 2004; 53: 75–90.
Devlin B, Roeder K . Genomic control for association studies. Biometrics 1999; 55: 997–1004.
Clayton D In: Balding DJ, Bishop M, Cannings C (eds). Handbook of Statistical Genetics. Wiley: Chichester, 2001, pp 519–540.
Schneider S, Roesli D, Excoffier L . Arlequin: A Software for Population Genetics Data Analysis Version 2.0. Genetics and Biometry Laboratory, University of Geneva: Geneva, 2000. http://anthropologie.uige.ch/arlequin.
Lewontin RC . The detection of linkage disequilibrium in molecular sequence data. Genetics 1995; 140: 377–388.
Herr M, Dudbridge F, Zavattari P et al. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum Mol Genet 2000; 9: 1291–1301.
Zhao JH, Sham PC . Faster allelic association analysis using unrelated subjects. Hum Hered 2002; 53: 36–41.
Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL . A new algorithm for haplotype-based association analysis: the stochastic EM algorithm. Ann Hum Genet 2004; 68: 165–177.
Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA . Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445–1463.
Maggi CA . The effect of tachykinins on inflammatory and immune cells. Regul Peptides 1997; 70: 75–90.
Kostyk SK, Kowall NW, Hauser SL . Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res 1989; 504: 284–288.
Palma C, Minghetti L, Astolfi M et al. Functional characterization of substance P receptors on culture human spinal chord astrocytes; synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin-E2 production. Glia 1997; 21: 183–193.
Martin FC, Anton PA, Gornbein JA, Shanahan F, Merrill JE . Production of interleukin-1 by microglia in response to substance P – role for a non-classical NK-1 receptor. J Neuroimmunol 1993; 42: 53–60.
Lubernarod J, Kage R, Leeman SE . Substance P enhances the secretion of tumor necrosis factor alpha from neuroglial cells stimulated with lipopolysaccharide. J Immunol 1994; 152: 819–824.
Fiebich BL, Schleier S, Butcher RD, Craig A, Lieb K . The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independent from NF-κB. J Imunol 2000; 165: 5606–5611.
Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K . The neuropeptide substance P activates transcription factor NF-κB and κB-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159: 4952–4958.
Annunziata P, Cioni C, Santonini R, Paccagnini E . Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol 2002; 131: 41–49.
Quinlan KL, Naik SM, Cannon G et al. Substance P activates coincident NF-AT and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 1999; 163: 5656–5665.
McCluskey LP, Lampson LA . Local immune regulation in the central nervous system by substance P vs glutamate. J Neuroimmunol 2001; 116: 136–146.
O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F . The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167–180.
Acknowledgements
This study was supported with a research grant from The Multiple Sclerosis Society of Ireland (http://www.ms-society.ie/) to KV and SH. This study was given ethics approval by the Queen's University Belfast Research Ethics Committee.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cunningham, S., Patterson, C., McDonnell, G. et al. Haplotype analysis of the preprotachykinin-1 (TAC1) gene in multiple sclerosis. Genes Immun 6, 265–270 (2005). https://doi.org/10.1038/sj.gene.6364175
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.gene.6364175
Keywords
This article is cited by
-
Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFNγ/IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis
Journal of Neuroimmune Pharmacology (2015)
-
Association of genetic variants in tachykinins pathway genes with colorectal cancer risk
International Journal of Colorectal Disease (2012)
-
Multiple sclerosis genetics: leaving no stone unturned
Genes & Immunity (2005)